首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >EFFICACY AND SAFETY PROFILE OF LENVATINIB AND SORAFENIB IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED RADIOACTIVE-IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RR-DTC)

【24h】

EFFICACY AND SAFETY PROFILE OF LENVATINIB AND SORAFENIB IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED RADIOACTIVE-IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RR-DTC)

机译：LENVATINIB和SORAFENIB在先进的放射性-碘-碘耐药性甲状腺癌（RR-DTC）治疗成人患者中的功效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Kawalec P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. EFFICACY AND SAFETY PROFILE OF LENVATINIB AND SORAFENIB IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED RADIOACTIVE-IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RR-DTC) [J] . Kawalec P. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：LENVATINIB和SORAFENIB在先进的放射性-碘-碘耐药性甲状腺癌（RR-DTC）治疗成人患者中的功效和安全性
2. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy [J] . Locati L. D., Piovesan A., Durante C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Lenvatinib的真实疗效和安全性：来自富于富含放射性碘 - 难治分化的甲状腺癌患者的富有同情心使用的数据
3. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer [J] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, BMC Cancer . 2011,第1期

机译：决策的原理和设计：一项双盲，随机，安慰剂对照的III期临床试验，评估索拉非尼在局部晚期或转移性放射性碘（RAI）难治性分化型甲状腺癌患者中的疗效和安全性
4. Clinical Engineering and Clinical Dosimetry in Patients with Differentiated Thyroid Cancer Undergoing Thyroid Remnant Ablation with Radioiodine-131 [C] . M. Medvedec, D. Dodig 12th Mediterranean conference on medical and biological engineering and computing 2010 . 2010

机译：放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
5. Risk of Advanced Papillary Thyroid Cancer in Obese Patients. [D] . Harari, Avital. 2013

机译：肥胖患者晚期乳头状甲状腺癌的风险。
6. A systematic review of lenvatinib and sorafenib for treating progressive locally advanced or metastatic differentiated thyroid cancer after treatment with radioactive iodine [O] . Nigel Fleeman, Rachel Houten, Marty Chaplin, 2019

机译：来伐替尼和索拉非尼用于放射性碘治疗后进行性局部晚期或转移性分化型甲状腺癌的系统评价
7. 426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg [O] . M.S. Brose, Y. Panaseykin, B. Konda, 2020

机译：426P多中心，随机，双盲，二期患者（PTS）在患者（PTS）中的甲状腺抑菌分化甲状腺癌（RR-DTC）进行评估，评价每日口服起始剂量为18毫克的安全性和功效vs 24 mg.

相关主题

获取原文

期刊订阅

抱歉，该期刊暂不可订阅，敬请期待！

目前支持订阅全部北京大学中文核心（2020）期刊目录。

暂不订阅

继续订阅其他期刊

意见反馈

回到顶部

回到首页

关于掌桥

资源导航

新手指南

常见问题

网站地图

版权声明

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信

服务号